Imperial College London
Portrait Picture

ProfessorThomasBarnes

Faculty of Medicine, Department of Brain Sciences

Emeritus Professor of Clinical Psychiatry
 
 
 
//

Contact

 

t.r.barnes

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Deakin:2019,
author = {Deakin, B and Suckling, J and Dazzan, P and Joyce, E and Lawrie, SM and Upthegrove, R and Husain, N and Chaudhry, IB and Dunn, G and Jones, PB and Lisiecka-Ford, D and Lewis, S and Barnes, TRE and Williams, SCR and Pariante, CM and Knox, E and Drake, RJ and Smallman, R and Barnes, NM},
title = {Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <h4>Background</h4>In a previous trial we reported that the neuroprotective, anti-inflammatory antibiotic minocycline lessened the negative symptoms of schizophrenia compared with placebo over 1 year. The BeneMin study aimed to replicate this benefit and to determine whether or not there was associated preservation of grey matter, reduction in circulating inflammatory cytokines and enhancement of cognition.<h4>Objectives</h4>To determine the efficacy of minocycline on the negative symptoms of schizophrenia and the mechanistic role of neuroprotective, anti-inflammatory and cognitive enhancing actions.<h4>Methods</h4>Two hundred and seven patients with a current research diagnosis of schizophrenia within 5 years of onset were randomised by a permuted blocks algorithm to minocycline (300 mg/day) or matching placebo as an adjunct to their continuing treatment. The primary efficacy outcome variable was the negative symptom subscale score from the Positive and Negative Syndrome Scales at 2, 6, 9 and 12 months. The primary mechanistic (biomarker) variables were (1) medial prefrontal grey matter volume (GMV), (2) circulating cytokine interleukin (IL) 6 concentration and (3) dorsolateral prefrontal cortex functional magnetic resonance imaging (fMRI) activations during performance of the N-back task. Movement disorder, side effects and treatment adherence were monitored throughout the study.<h4>Results</h4>Compared with placebo, the addition of minocycline had no effect on the severity of negative symptoms [treatment effect difference –0.186, 95% confidence interval (CI) –1.225 to 0.854] across the 2-, 6-, 9- and 12-month follow-up visits. None of the mechanistic biomarkers was influenced by minocycline: left GMV –91.2 (95% CI –303.8 to 121.4), IL-6 0.072 (95% CI –0.118 to 0.262) and N-back fMRI 0.66 (95% CI –1.53 to 0.20). There were no statistically significant treatment effects on an
AU  - Deakin,B
AU  - Suckling,J
AU  - Dazzan,P
AU  - Joyce,E
AU  - Lawrie,SM
AU  - Upthegrove,R
AU  - Husain,N
AU  - Chaudhry,IB
AU  - Dunn,G
AU  - Jones,PB
AU  - Lisiecka-Ford,D
AU  - Lewis,S
AU  - Barnes,TRE
AU  - Williams,SCR
AU  - Pariante,CM
AU  - Knox,E
AU  - Drake,RJ
AU  - Smallman,R
AU  - Barnes,NM
PY  - 2019///
TI  - Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
ER  -
Download